INSIGHTS ON DRUG DEVELOPMENT

• Strategies For Optimizing Upstream Processes Cell Culture

  The cell culture process is crucial for maximizing the production of biologics and vaccines, optimizing product quality attributes, minimizing impurities, and simplifying operations.

• Optimizing Process Efficiency In Upstream Manufacturing

  Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency — a key goal for biopharma production.

• Enhanced Host Cell Protein Analysis In Biologics Manufacturing

  The most widely used and accepted method to monitor host cell protein levels in biologics is an immunological assay, Enzyme-Linked Immunosorbent Assay, also known as ELISA. However, this coverage assay comes with some known challenges. Learn more about an enhanced anti-host cell protein antibody coverage analysis method solution.

• Zydis® Bio Technology, Grazax® & Grastek®: Revolutionizing Allergy Therapy

  ALK-Abelló is a global research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies. Before ALK-Abelló partnered with Catalent, all marketed allergen immunotherapies were delivered by injection, resulting in a limited patient population and reduced patient adherence. Catalent worked with the client to apply Zydis Fast Dissolve Technology to their therapy, bringing a vastly superior product to market.

• A Plasma Problem: Dwindling Supply In The Face Of A Growing Demand

  An outlook on the market shows plasma fractionators will have to look to innovation and other opportunities for supply, in order to meet the needs of patients.

• Create Brand Sustainability With Softgel Technology

  Keeping an eye on some emerging trends that are shaping society and the pharmaceutical industry can help you meet diverse consumer preferences and potentially extend product lifecycles.

• Zydis® ODT Provides Better Treatments

  Discover how Catalent's oral drug delivery offerings can help get your molecule to market faster. In this case study, learn the many benefits of our product offerings.

• Single-Use Platforms Accelerate Viral Vaccine Development And Manufacturing

  Biopharma analysts predict the market for vaccines could grow at a compound annual growth rate of as much as 10.3 percent through 2024. Single-use platforms that eliminate reinvention of the wheel for each candidate might be pivotal to meeting that demand.

• Analytical Solutions For Manufacturing Powders And Particles

  The properties of the particles that make up a pharmaceutical powder directly affect its behavior, a classic example being that finer particles are usually associated with poor flowability.